Q-omics provides the consensus-scored KCNE5 profile across patient tissues and cancer cell-line models. KCNE5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KCNE5 is differentially expressed in 14, with the highest sampling consensus in BRCA. Additionally, KCNE5 RNA expression shows 11,167 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight MESO, BRCA, and PAAD as cancer lineages where KCNE5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNE5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNE5 survival associations across molecular data types. KCNE5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNE5 RNA expression–survival associations across cancer types. High KCNE5 expression shows unfavorable associations in MESO, LIHC, LGG and KIRC, but favorable associations in SCLC and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for KCNE5 RNA expression.
This table summarizes KCNE5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KCNE5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNE5 shows lower tumor expression in BRCA, BLCA and KICH and higher tumor expression in LIHC, HNSC and UCEC. The BRCA box plot shows higher KCNE5 RNA expression in normal versus tumor tissue (log2 FC = −0.585, t-test p < 0.001).
This table shows molecular features associated with KCNE5 in patient tissues and cancer cell lines. In patient samples, KCNE5 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNE5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and OESOPHAGUS.
